For endogenous features. Sold as Nardil. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Phenelzine Sulfate (sold as Nardil), first approved Jun 9, 1961, with 0 new uses approved and 0 published complete response letters.
| Phenelzine Sulfate | Part D | $1.0M | -5% | 1,946 |
| Nardil | Part D | $97K | -10% | 49 |
| Jun 9, 1961 | NardilNDA 11909 · New molecular entity | Parke Davis | 13 | Marketed |
| Dec 8, 2010 | Phenelzine SulfateANDA 200181 | Novel Labs Inc | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Parke Davis